IMPINJ INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IMPINJ INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $122.63M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $125.30M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $112.29M | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $361.08M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $366.09M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $307.54M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $257.80M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $190.28M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $138.92M | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $152.84M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $122.63M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $125.30M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $112.29M | Feb 28, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $125.30M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $112.29M | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | $78.48M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $63.76M | Mar 3, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.68M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $188.86M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $151.98M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $137.88M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $98.95M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $65.14M | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $74.00M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $58.28M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $64.94M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $59.45M | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.85M) | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $40.84M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | ($43.37M) | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | ($24.30M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | ($51.26M) | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | ($51.92M) | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | ($22.99M) | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | ($35.23M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | ($17.32M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($1.67M) | Feb 28, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($737.0K) | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | ($7.07M) | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | ($43.48M) | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | ($19.48M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | ($37.25M) | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | ($47.07M) | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | ($21.66M) | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | ($34.87M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | ($17.02M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($488.0K) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.62M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $98.83M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $88.56M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $74.11M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $64.06M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $48.59M | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $38.88M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $34.17M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $32.22M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $25.19M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.75M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $128.31M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | ($49.38M) | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $641.0K | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $6.47M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | ($16.88M) | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $4.71M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | ($11.78M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | ($35.89M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($9.50M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.86M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $17.11M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $18.59M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $12.08M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $16.23M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $3.07M | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $2.43M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $6.37M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $6.55M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $3.53M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $545.19M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $489.08M | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $359.41M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $349.74M | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $315.54M | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | $207.62M | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $215.05M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $145.07M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $152.03M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $167.54M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $335.96M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $339.22M | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $325.28M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $334.15M | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $326.61M | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | $98.50M | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $89.81M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $47.19M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $33.09M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $43.51M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.23M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $149.86M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $34.13M | Feb 9, 2026 |
| FY2025 | Dec 31, 2022 | $15.59M | Feb 9, 2026 |
| FY2024 | Dec 31, 2021 | ($11.08M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2020 | $109.12M | Feb 12, 2024 |
| FY2022 | Dec 31, 2019 | $125.24M | Feb 13, 2023 |
| FY2021 | Dec 31, 2018 | $97.88M | Feb 14, 2022 |
| FY2020 | Dec 31, 2017 | $118.94M | Feb 17, 2021 |
| FY2019 | Dec 31, 2016 | $124.02M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.72M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $18.72M | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | $19.70M | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | $3.88M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $3.88M | Feb 12, 2024 |
| FY2016 | Dec 31, 2016 | $3.88M | Mar 3, 2017 |
| FY2016 | Dec 31, 2015 | $3.88M | Mar 3, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($400.16M) | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | ($389.31M) | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | ($430.15M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | ($386.79M) | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | ($362.48M) | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | ($314.67M) | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | ($262.74M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | ($239.76M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($204.53M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($187.20M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.21M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $46.05M | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | $94.79M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $19.60M | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $123.90M | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | $23.64M | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $66.90M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $17.53M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $19.29M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $33.64M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.89M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | $283.49M | Feb 9, 2026 |
| FY2022 | Dec 31, 2022 | $280.24M | Feb 13, 2023 |
| FY2022 | Dec 31, 2021 | $288.29M | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | $54.56M | Feb 14, 2022 |
| FY2018 | Dec 31, 2018 | $23.67M | Feb 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 13, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 9, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 9, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 13, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.22M | Feb 9, 2026 |
| FY2025 | Dec 31, 2024 | 28.50M | Feb 9, 2026 |
| FY2024 | Dec 31, 2023 | 27.17M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | 26.10M | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | 24.74M | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | 23.35M | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | 22.22M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | 21.49M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 20.97M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 20.34M | Mar 15, 2018 |